

UCSF

UC San Francisco Previously Published Works

Title

Genetic association signal near NTN4 in Tourette syndrome

Permalink

<https://escholarship.org/uc/item/90v4775p>

Journal

Annals of Neurology, 76(2)

ISSN

0364-5134

Authors

Paschou, Peristera
Yu, Dongmei
Gerber, Gloria
[et al.](#)

Publication Date

2014-08-01

DOI

10.1002/ana.24215

Peer reviewed

Published in final edited form as:

Ann Neurol. 2014 August ; 76(2): 310–315. doi:10.1002/ana.24215.

Genetic association signal near *NTN4* in Tourette Syndrome

Peristera Paschou, PhD^{1,*}, Dongmei Yu, MS^{2,3}, Gloria Gerber, BA², Patrick Evans, PhD⁴, Fotis Tsetsos, BSc¹, Lea K. Davis, PhD⁴, Iordanis Karagiannidis, BSc¹, Jonathan Chaponis, BA², Eric Gamazon, MS⁴, Kirsten Mueller-Vahl, PhD⁵, Manfred Stuhmann, MD⁶, Monika Schloegelhofer, MA⁷, Mara Stamenkovic, MD⁷, Johannes Hebebrand, MD⁸, Markus Noethen, MD⁹, Peter Nagy, MD¹⁰, Csaba Barta, MD, PhD¹¹, Zsanett Tarnok, PhD¹⁰, Renata Rizzo, MD, PhD¹², Christel Depienne, PhD^{13,14,15}, Yulia Worbe, MD, PhD^{16,17}, Andreas Hartmann, MD^{16,17}, Danielle C. Cath, MD^{18,19}, Cathy L. Budman, MD^{20,21}, Paul Sandor, MD^{22,23}, Cathy Barr, PhD²², Thomas Wolanczyk, MD²⁸, Harvey Singer, MD²⁹, I-Ching Chou, MD^{30,31}, Marco Grados, MD, MPH³², Danielle Posthuma, PhD^{33,34,35}, Guy A. Rouleau, MD, PhD³⁶, Harald Aschauer, MD⁷, Nelson B. Freimer, MD³⁷, David L. Pauls, PhD², Nancy J. Cox, PhD^{#,4}, Carol A. Mathews, MD^{38,#}, and Jeremiah M. Scharf, MD, PhD^{2,3,39,40,#,*}

¹Department of Molecular Biology and Genetics, Democritus University of Thrace, Alexandroupoli, Greece ²Psychiatric and Neurodevelopmental Genetics Unit, Center for Human Genetics Research, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA ³Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA ⁴Section of Genetic Medicine, Department of Medicine, University of Chicago, Chicago, Illinois, USA ⁵Department of Psychiatry, Socialpsychiatry and Psychotherapy, Medizinische Hochschule Hannover, Germany ⁶Department of Human Genetics, Medizinische Hochschule Hannover, Germany ⁷Division of Biological Psychiatry, Department of Psychiatry and Psychotherapy, Medical University Vienna, Austria ⁸Department of Child and Adolescent Psychiatry, University of Duisburg-Essen, Essen, Germany ⁹Department of Genomics, Life and Brain Center, Institute for Human Genetics, University of Bonn, Bonn, Germany ¹⁰Vadaskert Child and Adolescent Psychiatric Hospital, Budapest, Hungary ¹¹Institute of Medical Chemistry, Molecular Biology and Pathobiochemistry, Semmelweis

*Corresponding authors: Jeremiah Scharf, M.D., Ph.D. Psychiatric & Neurodevelopmental Genetics Unit Massachusetts General Hospital Simches Research Building, 6th Floor 185 Cambridge Street Boston, MA 02114 TEL: 617-643-3139 FAX: 617-726-0830 jscharf@partners.org Peristera Paschou, PhD Dept. of Molecular Biology and Genetics Democritus University of Thrace Panepistimioupoli, Dragana Alexandroupoli 68100 Greece TEL: +302551030658 FAX: +302551030613 ppasschou@mbg.duth.gr.
#Co-senior author

Author Contributions Gilles de la Tourette Syndrome GWAS Replication Initiative (GGRI) Steering Committee: H Aschauer, IC Chou, NJ Cox, NB Freimer, M Grados, CA Mathews (co-chair), P Paschou (co-chair), DL Pauls, D Posthuma, GA Rouleau, JM Scharf (co-chair)

GGRI Study Design Group: H Aschauer, C Barr, C Barta, DC Cath, IC Chou, NJ Cox, LK Davis, C Depienne, P Evans, NB Freimer, G Gerber, M Grados, A Hartmann, J Hebebrand, I Karagiannidis, CA Mathews (co-chair), K Mueller-Vahl, P Nagy, M Noethen, P Paschou (co-chair), DL Pauls, D Posthuma, R Rizzo, GA Rouleau, P Sandor, JM Scharf (co-chair), H Singer, M Stuhmann, Z Tarnok, T Wolanczyk, Y Worbe, D Yu

GGRI Phenotype Harmonization and Data Analysis Committee: H Aschauer, CL Budman, D Cath, IC Chou, M Grados, CA Mathews (Chair), P Nagy, R Rizzo, P Sandor, JM Scharf, M Schloegelhofer, M Stamenkovic, T Wolanczyk

GGRI Genetic Data Analysis Committee: P Paschou, D Yu, G Gerber, P Evans, F Tsetsos, LK Davis, J Chaponis, E Gamazon, NB Freimer, DL Pauls, NJ Cox, CA Mathews, JM Scharf

Disclosures The other authors declare no conflict of interest.

Additional supplementary methods are available by request from the corresponding authors.

University, Budapest, Hungary ¹²Dipartimento di Scienze Mediche e Pediatriche, Università di Catania, Italy ¹³Centre de Recherche de l'Institut du Cerveau et de la Moelle Epinière, Paris, France ¹⁴INSERM UMR 975 - CRICM, Institut du cerveau et de la moelle épinière (ICM), Hôpital Pitié-Salpêtrière, Paris, France ¹⁵Université Pierre et Marie Curie-Paris-6 (UPMC), UMR_S 975, Paris, France ¹⁶Centre de Référence National Maladie Rare: 'Syndrome Gilles de la Tourette', Paris, France ¹⁷Département de Neurologie & Centre de Recherche de l'Institut du Cerveau et de la Moelle Epinière, Paris, France ¹⁸Department of Clinical & Health Psychology, Utrecht University, Utrecht, Netherlands ¹⁹Department of Psychiatry, VU University Medical Center, Amsterdam, Netherlands ²⁰Hofstra University School of Medicine, Hempstead, NY, USA ²¹North Shore-Long Island Jewish Health System, Manhasset, NY, USA ²²Toronto Western Research Institute, University Health Network, Toronto, ON, Canada ²³Youthdale Treatment Centers, Toronto, Ontario, Canada ²⁴Department of Medical Research, China Medical University Hospital, Taichung, Taiwan ²⁵School of Post Baccalaureate Chinese Medicine, China Medical University, Taichung, Taiwan ²⁶Department of Pediatrics and Medical Research, China Medical University Hospital, Taichung, Taiwan ²⁷School of Chinese Medicine, China Medical University, Taichung, Taiwan ²⁸Department of Child Psychiatry, Medical University of Warsaw, Warsaw, Poland ²⁹Johns Hopkins University School of Medicine, Baltimore, MD, USA ³⁰Department of Pediatrics, China Medical University Hospital, Taichung, Taiwan ³¹Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan ³²Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA ³³Department of Functional Genomics, Center for Neurogenomics & Cognitive Research, Neuroscience Campus Amsterdam, Vrije Universiteit Amsterdam, Netherlands ³⁴Complex Trait Genetics, Department of Clinical Genetics, Vrije Universiteit Medical Center, Amsterdam, The Netherlands ³⁵Department of Child and Adolescent Psychiatry, Erasmus University Medical Center, Sophia Child's Hospital, Rotterdam, The Netherlands ³⁶Montreal Neurological Institute and Hospital, Department of Neurology and Neurosurgery, McGill University, Montreal, Canada ³⁷Center for Neurobehavioral Genetics, Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles, Los Angeles, CA, USA ³⁸Department of Psychiatry, University of California at San Francisco, San Francisco, CA, USA ³⁹Department of Neurology, Massachusetts General Hospital, Boston, MA, USA ⁴⁰Division of Cognitive and Behavioral Neurology, Brigham and Womens Hospital, Boston, MA, USA

Abstract

Tourette Syndrome (TS) is a neurodevelopmental disorder with a complex genetic etiology. Through an international collaboration, we genotyped 42 single nucleotide polymorphisms (SNPs) ($p < 10^{-3}$) from the recent TS genome-wide association study (GWAS) in 609 independent cases and 610 ancestry-matched controls. Only rs2060546 on chromosome 12q22 ($p = 3.3 \times 10^{-4}$) remained significant after Bonferroni correction. Meta-analysis with the original GWAS yielded the strongest association to date ($p = 5.8 \times 10^{-7}$). Although its functional significance is unclear, rs2060546 lies closest to *NTN4*, an axon guidance molecule expressed in developing striatum. Risk score analysis significantly predicted case/control status ($p = 0.042$), suggesting that many of these variants are true TS risk alleles.

Introduction

Tourette Syndrome (TS) is a highly heritable, childhood-onset neurodevelopmental disorder that is thought to arise from a complex genetic background interacting with additional environmental factors, underlining the need for large-scale genetic studies and replication of results in independent cohorts (Paschou, 2013). Here, following up on the first genome-wide association study (GWAS) for TS (Scharf et al. 2013), we analyzed an independent European-ancestry sample for 42 top variants of interest in the initial GWAS and provide evidence for enhanced association for one of these single nucleotide polymorphisms (SNPs) (rs2060546 on 12q22) with TS.

The GWAS performed by the Tourette Syndrome Association International Consortium for Genetics (TSAICG) (Scharf et al. 2013) is the first large-scale TS effort in a field that has been hampered by fragmented experiments from individual laboratories and small sample sizes. In this study of 1,285 TS-affected individuals and 4,964 European-ancestry controls, the top signals ($p < 1 \times 10^{-3}$) were significantly enriched for functional variants associated with gene expression and/or methylation levels in cerebellum or frontal cortex (eQTLs/mQTLs, expression quantitative trait loci or methylation quantitative trait loci), although no single marker attained genome-wide significance ($p < 5 \times 10^{-8}$) (Pe'er et al. 2008, Dudbridge & Gusnanto 2008). Subsequent analyses of TS genetic architecture confirmed that the majority of TS heritability is captured by GWAS SNPs with allele frequencies $> 5\%$ (Davis et al. 2013), although disproportionate heritability could be attributed to rarer variants. These discoveries underline the genetic complexity of the disorder, and highlight the value of follow-up studies in additional samples.

Patients and Methods

The Gilles de la Tourette Syndrome Genome-wide Association Study Replication Initiative (GGRI) is a collaboration of European and North American TS investigators. We recruited 609 TS cases and 610 ancestry-matched controls from Hungary (73 cases/93 controls), Germany (129 cases/185 controls), Austria (92 cases/103 controls), Italy (47 cases/44 controls), Greece (17 cases/49 controls), and Canada (French Canadian origin, 151 cases/136 controls). Participants aged 18 and older provided written, voluntary informed consent for participation. Individuals under 18 provided assent; written parental consent was also obtained. The study was approved by the Ethics Committees of all participating sites.

Forty-three SNPs, including the top 20 linkage disequilibrium (LD)-independent GWAS hits ($r^2 < 0.2$) and 23 additional SNPs with $p_{\text{GWAS}} < 1 \times 10^{-3}$ that were either eQTL/mQTLs of interest (as described in Scharf et al., 2013) or located within 50kb of previously identified candidate genes for TS or related neuropsychiatric disorders, were selected for targeted genotyping (Table S1). Seventy-four additional ancestry-informative markers (AIMs) were also genotyped to control for population substructure (Table S2). Genotyping was performed using primer extension and mass spectrophotometry (Sequenom, San Diego, CA, USA) as previously described (Crane et al. 2011).

Principal components analysis (PCA) was performed using EIGENSTRAT (Price et al. 2006) to exclude outliers based on observed genetic ancestry and to produce population structure covariates to correct for residual population stratification. One follow-up SNP failed genotyping, leaving 42 for analysis (Table S1). Genetic association analysis was conducted in PLINK (Purcell et al. 2007) using logistic regression under an additive model with the first two principal components, representing the major axes of variation in genetic ancestry of the sample (North-South and East-West European clines), included as covariates. Meta-analysis with the European-ancestry samples of the original TS GWAS (1,285 TS cases and 4,964 ancestry-matched controls) was performed in METAL (Willer et al. 2010).

A TS risk score was calculated based on the 42 SNPs in each GGRI case/control subject, representing a sum of the number of risk alleles present weighted by the effect size of each locus as estimated in the initial TS GWAS. The relationship between TS risk score and case-control status was then examined by logistic regression (risk score analysis) with number of genotypes included as a covariate to control for any potential bias related to SNP missingness. The percentage of phenotypic variance explained by the aggregate risk score (Nagelkerke's pseudo- R^2) was also estimated.

Results

One SNP, rs2060546, was significantly associated with TS in the GGRI sample ($p=3.3\times 10^{-4}$, OR=2.41) after Bonferroni correction (corrected threshold for nominal significance set at $p=0.05/42$ SNPs = 0.0012) (Table 1, Table S3). Combined analysis of the original GWAS and GGRI samples for this SNP (1,894 cases and 5,574 controls) yielded an association p -value= 5.8×10^{-7} and a combined OR=1.77, strengthening the evidence for association relative to the original GWAS ($p_{\text{GWAS}}<3.7\times 10^{-4}$, OR=1.60). The association signal from the top SNP in the initial GWAS, rs7868992, located in an intronic region of *COL27A1* (collagen type XXVII, alpha 1 chain), was marginally weaker than the signal in the original study (GGRI OR=1.11, $p=0.26$; GWAS OR=1.29, $p=1.9\times 10^{-6}$; combined meta-analysis $p=6.4\times 10^{-6}$) (Table 1), with the same direction of effect. Although no other SNPs were nominally significant after experiment-wide correction in the GGRI sample, 26 of the 42 SNPs yielded the same direction of effect as in the original GWAS (one-sided binomial sign-test, $p=0.08$) (Table S3). Furthermore, the 42-SNP TS risk score significantly predicted TS case-control status in the GGRI sample ($p=0.042$), accounting for 0.52% of TS phenotypic variance.

Discussion

The top TS-associated SNP in our targeted genotyping study (rs2060546) lies in an intergenic region on chromosome 12q22, ~32kb distal (telomeric) to *NTN4*, and proximal to *SNRPF* (37kb) and *CCDC38* (45kb). SNRPF (small nuclear ribonucleoprotein polypeptide F) is a core component of the RNA spliceosome (Hermann et al. 1995), while the function of CCDC38 is unclear. NTN4 belongs to a family of extracellular proteins that direct axon outgrowth and guidance (Lai Wing Sun et al. 2011). In the developing nervous system, netrins interact with other axon guidance molecules, such as SLIT and WNT family members, to direct the trajectory of the growth cone at the tip of the migrating axon towards

its final target (Killeen and Sybingco 2008). *SLITRK1*, whose protein bears great similarity to the SLIT family, represents one of the most debated genes in the TS literature, as it has been reported to be associated with TS in a number of studies (Abelson et al. 2005, Karagiannidis et al. 2012), but not in a large family-based investigation of the original association (Scharf et al., 2008). *SLITRK1* was not implicated in the TS GWAS; however, the intergenic region between *SLITRK1* and *SLITRK6* yielded one of the top signals (rs7336083; $p=9.5\times 10^{-6}$, OR 0.80) (Scharf et al. 2013). Thus, *NTN4* is a strong candidate for a TS susceptibility gene; in fact, rs2060546 was selected for the current experiment based on having a $p<10^{-3}$ in the initial TS GWAS and being in linkage disequilibrium ($D'=1$) with the 5' end of *NTN4*.

However, it is not yet clear whether rs2060546 has any functional effect on either *NTN4* or other genes in this region. Although *NTN4* is the closest gene to rs2060546, recent work from the ENCODE and Roadmap Epigenomics consortia have demonstrated that ~40% of genome-wide significant GWAS SNPs lie in putative enhancer regions whose chromatin structure is most highly correlated with active promoters of genes >250kb from the putatively causal SNP (Maurano et al., Science 2012). While rs2060546 was not identified as a regulatory eQTL SNP in frontal lobe or cerebellum (Scharf et al., 2013), it appears to be a modest cis-eQTL in non-neural tissues for genes near *NTN4*, including two histidine catabolism genes, *HAL* (histidine ammonia-lyase, $p=0.0012$) and *AMDHD1* (amidohydrolase containing domain 1, $p=0.002$) in lymphoblast cell lines and *METAP2* (methionine aminopeptidase 2, $p=0.0009$) in adipose tissue (Stranger et al. 2012; Elbein et al., 2012). Impaired conversion of histidine to histamine via mutations in a third histidine catabolism gene *HDC* has been reported in one TS family, though whether this translates to TS risk in general or might involve other histidine-related pathways is uncertain (Erdan-Sencicek et al., 2010; Karagiannidis et al., 2013; Castellan-Baldan et al., 2013). Therefore, should further analyses confirm rs2060546 as a TS susceptibility variant, functional studies will be needed to determine the causative gene(s) at this locus and the biological mechanism through which this non-coding variant might contribute to this neurodevelopmental disorder.

A few limitations should be considered. While we took specific steps to control for bias from population stratification, including the use of ancestry-matched cases and controls and a carefully selected AIMS panel to detect outliers, in the absence of genome-wide data, it is possible that residual population stratification could have introduced bias. However, the rs2060546 risk allele frequency is consistently increased in cases compared to controls from each of the 6 GGRI countries, suggesting that the association is unlikely to be caused solely by residual population stratification (data not shown). In addition, the current sample is still underpowered to detect the majority of GWAS variants with effect sizes similar to those found in other neuropsychiatric disorders (Sullivan et al., 2012). However, the finding that a TS risk score combining all 42 SNPs in this study predicted TS case-control status suggests that, although not reaching genome-wide significance in this sample, a significant number of these variants are likely to be true TS susceptibility alleles. These results underline the need for future collaborative efforts in larger TS samples to clarify the potential significance of all variants in the current analysis and to identify definitive TS susceptibility genes.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The authors are grateful to all the patients with Tourette Syndrome who generously agreed to participate in this study. We would also like to acknowledge contributions from additional members of the Gilles de la Tourette Syndrome GWAS Replication Initiative (GGRI): L. Osiecki, C. Illmann, G Löber, M Gulisano, L Chen, W-D Lin, and F-J Tsai. This work was supported by NIH grants NS040024 to DLP, JMS and the Tourette Syndrome Association International Consortium for Genetics, NIH grant NS016648 to DLP, American Recovery and Reinvestment Act (ARRA) Grants NS040024-07S1 and NS016648-29S1 to DLP, NIH grant NS037484 to NBF, and NIH grant MH085057 to JMS. The study was also supported by the Tourette Syndrome Association, USA and COST Action BM0905.

Drs. Scharf and Mathews have received research support from the NIH and the Tourette Syndrome Association (TSA) on behalf of the TSA International Consortium for Genetics (TSAICG). Drs. Scharf and Mathews have also received honoraria and travel support from the TSA and are members of the TSA Medical Advisory Board (CAM) and Scientific Advisory Board (JMS). Dr. Paschou has received support from the TSA and the European Commission (COST Action BM0905, FP7-HEALTH EMTICS, FP7-PEOPLE TS-EUROTRAIN). Dr. Budman is a speaker for National TSA-CDC partnership, is funded in clinical research by Otsuka Pharmaceuticals and by Astra Zeneca, and is a member of the Long Island TSA and CHADD medical advisory boards. Dr. Grados has received honoraria from the TSA for travel support and been a site collaborator for NIH-funded grants to the TSA. Dr. Hebebrand receives support from the Deutsche Forschungsgemeinschaft for family studies of TS patients. Dr. Nagy has participated in TS-related clinical studies funded by Otsuka Pharmaceuticals. Dr. Sandor has received research funding from Otsuka, UCB Pharma and Cell Tech for unrelated pharmacological research studies. Dr. Tarnok has participated in TS-related clinical studies funded by Otsuka Pharmaceuticals. Dr. Yu has received research support from the Tourette Syndrome Association (TSA) and NIH.

None of the funding agencies for this project (NINDS, NIMH, the Tourette Syndrome Association and COST Action) had any influence or played any role in a) the design or conduct of the study; b) management, analysis or interpretation of the data; c) preparation, review or approval of the manuscript.

References

- Abelson JF, Kwan KY, O'Roak BJ, Baek DY, et al. Sequence variants in *SLITRK1* are associated with Tourette's syndrome. *Science*. 2005; 310(5746):317–20. [PubMed: 16224024]
- Castellan Baldan L, Williams KA, Gallezot JD, Pogorelov V, Rapanelli M, Crowley M, et al. Histidine decarboxylase deficiency causes Tourette Syndrome: parallel findings in humans and mice. *Neuron*. 2014; 81(1):77–90. [PubMed: 24411733]
- Crane J, Fagerness J, Osiecki L, Gunnell B, Stewart SE, Pauls DL, Scharf JM, Tourette Syndrome International Consortium for Genetics (TSAICG). Family-based genetic association study of *DLGAP3* in Tourette Syndrome. *Am J Med Genet B Neuropsychiatr Genet*. Jan; 2011 156B(1): 108–14. 2011. [PubMed: 21184590]
- Davis LK, Yu D, Keenan CL, Gamazon ER, et al. Partitioning the Heritability of Tourette Syndrome and Obsessive Compulsive Disorder Reveals Differences in Genetic Architecture. *PLOS Genetics*. 2013; 9(10):e1003864. [PubMed: 24204291]
- Dudbridge F, Gusnanto A. Estimation of significance thresholds for genomewide association scans. *Genet Epidemiol*. 2008; 32:227–234. [PubMed: 18300295]
- Elbein SC, Gamazon ER, Das SK, Rasouli N, Kern PA, Cox NJ. Genetic Risk Factors for Type 2 Diabetes: A *Trans*-Regulatory Genetic Architecture? *American Journal of Human Genetics*. 2012; 91(3):466–477. [PubMed: 22958899]
- Ercan-Sencicek AG, Stillman AA, Ghosh AK, Bilguvar K, et al. L-histidine decarboxylase and Tourette's syndrome. *N Engl J Med*. 2010; 362(20):1901–8. [PubMed: 20445167]
- Hermann H, Fabrizio P, Raker VA, Foulaki K, et al. snRNP Sm proteins share two evolutionarily conserved sequence motifs which are involved in Sm protein-protein interactions. *EMBO J*. 1995; 14(9):2076–88. [PubMed: 7744013]

- Karagiannidis I, Rizzo R, Tarnok Z, Wolanczyk T, et al. Replication of association between a SLITRK1 haplotype and Tourette Syndrome in a large sample of families. *Mol Psychiatry*. 2013; 17(7):665–8. [PubMed: 22083730]
- Karagiannidis I, Dehning S, Sandor P, Tarnok Z, et al. Support of the histaminergic hypothesis in Tourette syndrome: association of the histamine decarboxylase gene in a large sample of families. 2013; 50(11):760–4. doi: 10.1136/jmedgenet-2013-101637. Epub 2013 Jul 3.
- Killeen MT, Sybingco SS. Netrin, Slit and Wnt receptors allow axons to choose the axis of migration. *Dev Biol*. 2008; 323(2):143–51. [PubMed: 18801355]
- Lai Wing Sun K, Correia JP, Kennedy TE. Netrins: versatile extracellular cues with diverse functions. 2011; 138(11):2153–69.
- Maurano MT, Humbert R, Rynes E, et al. Systematic localization of common disease-associated variation in regulatory DNA. *Science*. 2012; 337:1190–1195. [PubMed: 22955828]
- Paschou P. The genetic basis of Gilles de la Tourette Syndrome. *Neurosci Biobehav Rev*. 2013; 37(6): 1026–39. [PubMed: 23333760]
- Pe'er I, Yelensky R, Altshuler D, Daly MJ. Estimation of the multiple testing burden for genomewide association studies of nearly all common variants. *Genet Epidemiol*. 2008; 32:381–385. [PubMed: 18348202]
- Price AL, Patterson NJ, Plenge RM, Weinblatt ME, et al. Principal components analysis corrects for stratification in genome-wide association studies. *Nature Genetics*. 2006; 38:904–909. [PubMed: 16862161]
- Purcell S, Neale B, Todd-Brown K, Thomas L, et al. PLINK: a toolset for whole-genome association and population-based Linkage analysis. *American Journal of Human Genetics*. 2007; 81(3):559–75. [PubMed: 17701901]
- Scharf JM, Moorjani P, Fagerness J, et al. Lack of association between SLITRK1var321 and Tourette syndrome in a large family-based sample. *Neurology*. 2008; 70:1495–1496. [PubMed: 18413575]
- Scharf JM, Yu D, Mathews CA, et al. Genome-wide association study of Tourette's syndrome. *Mol Psychiatry*. 2013; 18(6):721–8. [PubMed: 22889924]
- Stranger BE, Montgomery SB, Dimas AS, Parts L, Stegle O, Ingle CE, Sekowska M, et al. Patterns of *Cis* Regulatory Variation in Diverse Human Populations. *PLOS Genetics*. 2012 10.1371/journal.pgen.1002639.
- Sullivan PF, Daly MJ, O'Donovan M. Genetic architectures of psychiatric disorders: the emerging picture and its implications. *Nat Rev Neurosci*. 2012; 13:537–551.
- Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics*. 2010; 26(17):2190–1. [PubMed: 20616382]

Table 1
Top 10 association signals in the GGRI TS GWAS follow-up study (609 cases and 610 ancestry-matched controls)

Results of the original TS GWAS for these top linkage disequilibrium (LD)-independent SNPs as well as results of a meta-analysis of the replication and prior GWAS sample (total of 1894 cases and 5574 controls) are also shown. The closest genes around each SNP of interest and association with gene expression and/or methylation levels in cerebellar or frontal cortex tissue are also indicated.

CHR	SNP	BP (hg19)	AI/A2	MAF	TS GWAS		GGRI sample		Meta-analysis		Gene	eQTL/mQTL
					OR	P	OR	P	OR	P		
12	rs2060546	96,215,456	A/G	0.027	1.60	3.7×10 ⁻⁴	2.41	3.3×10 ⁻⁴	1.77	5.8×10 ⁻⁷	SNRPF NTN4 CCDC38	
2	rs1922786	58,863,573	G/A	0.35	0.83	2.1×10 ⁻⁴	0.76	2.4×10 ⁻³	0.81	1.9×10 ⁻⁶		SELIL2, LMAN1L, INSL3
9	rs7868992	116,991,071	G/A	0.28	1.29	1.9×10 ⁻⁶	1.11	0.26	1.24	6.4×10 ⁻⁶	COL27A1	SYTL4, AMBP, HSPC152, OAS2, PWPI, RALBP1
11	rs11603305	10,997,949	G/A	0.28	1.27	1.3×10 ⁻⁵	1.16	0.10	1.24	7.2×10 ⁻⁶		
7	rs1882078	37,436,975	C/T	0.28	1.27	1.9×10 ⁻⁵	1.15	0.11	1.23	1.1×10 ⁻⁵	ELMO1	
12	rs6539267	106,785,554	C/T	0.31	0.79	7.4×10 ⁻⁶	0.90	0.22	0.82	1.1×10 ⁻⁵	TCPI1L2 POLR3B	TMEM119
7	rs769111	12,059,806	G/T	0.38	0.81	1.2×10 ⁻⁵	0.90	0.19	0.83	1.6×10 ⁻⁵		MEOX2, PLSCR1, PCDHB16
11	rs7123010	86,341,186	A/G	0.30	0.79	4.2×10 ⁻⁵	0.89	0.20	0.82	4.9×10 ⁻⁵	ME3	NFKBIZ, FLJ23514, KLF8, PICALM
11	rs621942	85,783,738	A/C	0.24	1.23	1.3×10 ⁻⁴	1.15	0.14	1.21	6.8×10 ⁻⁵	PICALM	TMEM126B, TMEM126A, PICALM, CREB3L3, LRRC2
3	rs2282755	50,442,800	T/G	0.28	0.80	5.6×10 ⁻⁵	0.90	0.24	0.82	7×10 ⁻⁵	TMEM115 CACNA2D2	ZMYND10, PTHIR, HYAL3, SEMA3G

CHR, Chromosome; **BP (hg19)**, Physical position according to NCBI Build 37/hg19 genome assembly; **AI/A2**, Allele 1/Allele 2 (Allele 1 is the minor allele); **MAF**, Minor Allele Frequency; **OR**, odds ratio; **P**, p-value of genetic association test; **eQTL/mQTL**, SNP associated with gene expression levels (cerebellum or frontal cortex) and/or methylation levels in cerebellum (as described in Scharf et al. 2013). Complete results of all 42 targeted SNPs are provided in Table S3.